Skip to main content

Table 1 Titration of BCLA in different clinical forms of toxoplasmosis

From: A brain cyst load-associated antigen is a Toxoplasma gondii biomarker for serodetection of persistent parasites and chronic infection

  BCLA [UI] IgG [IU/mL] (Architect) IgM [index] (Architect) IgG [IU/mL] (Vidas) IgM [index] (Vidas) Clinical context
Serological interpretation
 Negative < 65 < 1.6 < 0.5 < 4 < 0.55  
 Inconclusive 65–79 1.6–2.9 0.50–0.59 4–7 0.55–0.64  
 Positive ≥ 80 ≥ 3 ≥ 0.6 ≥ 8 ≥ 0.65  
Toxoplasma seronegative patients (n = 43)
Median [IC25–IC75] 30.1 [0–57.1] 0.1 [0–0.1] 0.09 [0.07–0.14] / /  
Patient 1 0 0.2 0.14 / / Immunocompetent/delivery
Patient 2 37.8 0.3 0.09 / / Immunocompetent/corneal transplant
Patient 3 115.3 0.1 0.07 / / Immunocompetent/otitis
Patient 4 69.6 0.2 0.12 / / Immunosupression/AIDS
Patient 5 16.1 0.1 0.06 / / Immunocompetent/pregnancy
Past immunity—chronic toxoplasmosis (n = 79)
Median [IC25–IC75] 102.6 [52.6–171.4] 29.7 [7.95–69.9] 0.19 [0.10–0.31] 132 [41–252] 0.07 [0.04–0.24]  
Patient 6 61.8 22.9 0.10 101 0.03 Immunocompetent/pregnancy
Patient 7 118.4 523 0.68 > 300 0.66 Immunocompetent/pregnancy
Patient 8 180.5 26.3 0.30 120 0.27 Immunosupression/dysglobulinemia
Patient 9 264.9 31.6 0.41 164 0.26 Immunocompetent/pregnancy
Patient 10 77.2 68.3 0.11 199 0.11 Immunocompetent/living kidney donor
Disseminated toxoplasmosis in immunocompromised patients (n = 9)
Median [IC25–IC75] 127.1 [20.3–294.9] 28.4 [1.4–269.9] 0.11 [0.08–0.13] 42 [2.5–300] 0.10 [0.04–0.21]  
Patient 11 0 1.3 0.12 2 0.24 Allogeneic HSCT/disseminated toxoplasmosis/positives PCR in BAF, buffy coat and CSF
Patient 12 40.5 / / 42 0.17 Allogeneic HSCT/cerebral toxoplasmosis/positives PCR in buffy coat and CSF
Patient 13 277.4 78.8 0.11 > 300 0.11 AIDS/cerebral toxoplasmosis/positives PCR in buffy coat and CSF
Patient 14 127.1 / / > 300 0.1 AIDS/cerebral toxoplasmosis/positive PCR in CSF
Patient 15 213.3 28.4 0.09 25 0.03 Neoplasia/pulmonary toxoplasmosis/positive PCR in BAF
Asymptomatic serological reactivation in immunocompromised patients (n = 7)
Median [IC25–IC75] 483.7 [190.6–1427.8] 359.0 [54.7–1254] 0.86 [0.26–4.93] 300 [26–300] 1.33 [0.22–5.26]  
Patient 16 235.1 1254 0.86 > 300 1.33 Allogeneic HSCT/3 negative PCR in buffy coat
Patient 17 701.8 936.4 0.26 > 300 0.04 Allogeneic HSCT
Patient 18 1427.8 359.0 2.68 > 300 2.76 Allogeneic HSCT/2 negative PCR in buffy coat
Patient 19 173.8 > 2000 0.17 > 300 0.26 Allogeneic HSCT
Patient 20 190.6 107.1 6.18 23 5.26 Allogeneic HSCT/2 negative PCR in buffy coat
Ocular toxoplasmosis (n = 18)
Median [IC25–IC75] 117.7 [47.1–227.9] 87.7 [25.6–405.5] 0.21 [0.09–1.53] 199 [135–300] 0.09 [0.04–0.86]  
Patient 21 46.6 / / 264 0.10 Immunosuppression/positive PCR in AH
Patient 22 167.7 71.5 0.22 178 0.14 Immunocompetent/positive PCR in AH
Patient 23 1622.2 > 2000 0.15 > 300 0.11 Immunocompetent/positive PCR in AH
Patient 24 75.5 11 0.09 48 0.04 Immunocompetent/production of antibodies in HA
Patient 25 193 370.8 9.01 209 4.99 Immunocompetent/production of antibodies in HA
  1. Toxoplasma IgG, IgM levels, and clinical context of five patients per clinical forms of toxoplasmosis are described (for all patients of this study cf. supplemental data)
  2. HSCT hematopoietic stem cell transplantation, AIDS acquired immunodeficiency syndrome, BAF broncho-alveolar fluid, CSF cerebro-spinal fluid, AH aqueous humor